Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
Authors
Keywords
-
Journal
Molecular Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-07-31
DOI
10.1002/1878-0261.12770
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor
- (2020) Marianne D. Sadar Expert Opinion on Drug Discovery
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
- (2019) Bertrand Tombal et al. LANCET ONCOLOGY
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
- (2019) Evangelia Kounatidou et al. NUCLEIC ACIDS RESEARCH
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
- (2018) Yundong He et al. NUCLEIC ACIDS RESEARCH
- Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
- (2018) Zhong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
- (2018) Howard I. Scher et al. JAMA Oncology
- Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
- (2018) Adam Sharp et al. JOURNAL OF CLINICAL INVESTIGATION
- Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer
- (2018) Chengfei Liu et al. Nature Communications
- AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide
- (2017) Anna Katharina Seitz et al. EUROPEAN UROLOGY
- Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells
- (2017) Ramakumar Tummala et al. MOLECULAR CANCER THERAPEUTICS
- EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
- (2016) Eva De Mol et al. ACS Chemical Biology
- Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
- (2016) Y. C. Yang et al. CLINICAL CANCER RESEARCH
- Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
- (2016) Fangfang Qu et al. CLINICAL CANCER RESEARCH
- Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
- (2016) Jonathan Welti et al. EUROPEAN UROLOGY
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
- (2015) D. Xu et al. CANCER RESEARCH
- Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
- (2015) Wendy Onstenk et al. EUROPEAN UROLOGY
- The Cistrome and Gene Signature of Androgen Receptor Splice Variants in Castration Resistant Prostate Cancer Cells
- (2015) Ji Lu et al. JOURNAL OF UROLOGY
- FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer
- (2015) Dominic Jones et al. Oncotarget
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
- (2015) Bo Cao et al. Oncotarget
- Homozygous Deletions and Recurrent Amplifications Implicate New Genes Involved in Prostate Cancer
- (2015) Wennuan Liu et al. NEOPLASIA
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Role of Androgen Receptor in Progression of LNCaP Prostate Cancer Cells from G1 to S Phase
- (2013) Shalini Murthy et al. PLoS One
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor and its splice variants in prostate cancer
- (2011) Simon Haile et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells
- (2010) Harri Makkonen et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now